2025第十九届沙利文全球增长、科创与领导力峰会暨第四届新投资大会于8月27日在上海召开。云晟研新凭借在改良型新药领域的卓越成就，荣膺2025年度「全球改良型新药年度企业奖」。

The 19th Frost & Sullivan Global Growth, Innovation & Leadership Summit and the 4th New Investment Conference was held in Shanghai on August 27, 2025.  In recognition of its exceptional achievements in the field of improved new drugs, Yunsun was awarded the prestigious "2025 Global Improved New Drug Company of the Year" title.

沙利文增长、科创与领导力最佳实践奖（简称：GIL奖项）旨在表彰各行业中作出突出贡献，取得领导地位的杰出企业。在全球范围内经过近30年的发展，奖项的权威性和公正性受到投资界和金融界及行业内的广泛认可。

The Frost & Sullivan Global Growth, Innovation & Leadership Award (abbreviated as the GIL Award) aims to recognize outstanding companies that have made significant contributions and achieved leadership positions in their respective industries. With nearly three decades of global development, the award's authority and impartiality are widely acknowledged by the investment and financial sectors, as well as within various industries. 

沙利文合伙人兼中东、南亚、北非区总裁Robin Joffe和中国肝炎防治基金会理事长、沙利文全球专家顾问团专家顾问、2024沙利文大中华区特别贡献奖得主王宇教授为上海云晟研新生物科技有限公司代表颁奖。

Mr. Robin Joffe, Partner and President of Frost & Sullivan for the Middle East, South Asia, and North Africa, alongside Professor Wang Yu, Chairman of the China Hepatitis Prevention and Treatment Foundation, Expert Advisor to Frost & Sullivan’s Global Advisory Council, and recipient of the 2024 Frost & Sullivan Greater China Special Contribution Award, presented the honor to the representative of Shanghai Yunsun Biopharm Co., Ltd.

改良型新药通过在已上市药品的基础上进行结构、剂型、处方工艺、给药途径或适应症的优化，展现出明显的临床优势。近年来，改良型新药在严肃医疗和消费医疗方面都有不俗表现。

Improved new drugs demonstrate significant clinical advantages by optimizing the structure, formulation, process technology, route of administration, or indications of already marketed pharmaceuticals. In recent years, they have shown remarkable performance in both serious medicine  and consumer medical care.

云晟研新专注于创新药/改良型新药的研发,在口服给药、注射给药、肺部给药、粘膜给药等多个给药技术领域构建了专长的药物递送技术平台。据公开信息显示，2022年至今其改良型新药申报项目数全国第一、临床批件受理量全国第二，已成为国内改良型新药的龙头企业。适应症涉及CNS，慢病，消化，肺部疾病等。

Yunsun has focused on the development of innovative drugs and improved new drugs. The company has established specialized drug delivery technology platforms covering various routes of administration, including oral, injectable, pulmonary, and mucosal delivery.According to public information, since 2022, the company has ranked first in the number of declared improved new drug projects and second in the acceptance of clinical approval applications nationwide.Indications cover CNS , chronic diseases, digestive disorders, pulmonary diseases, among others.

图1 2022年至今博志研新及云晟研新改良型新药申报情况

Figure 1. Declaration Status of Improved New Drugs by Bocimed and Yunsun Since 2022

数据来源：魔熵医药数据库

Sourced from: MoShang Pharmaceutical Intelligence Database

此次荣获2025沙利文“全球改良型新药年度企业奖项”，意味着云晟研新在全球医药创新的舞台上占据了重要的地位。这一荣誉不仅是对云晟研新自身研发实力和创新能力的肯定，也是中国研发企业在全球新药研发管线中贡献度逐步提升的一个缩影。

This award signifies that Yunsun has secured a significant position on the global stage of pharmaceutical innovation. This honor not only affirms Yunsun’s R&D capabilities and innovation strength, but also epitomizes the growing contribution of Chinese R&D enterprises to the global new drug development pipeline.

云晟研新将以此次获奖为新的起点，继续秉持创新精神，深耕改良型新药领域，不断拓展技术平台，丰富研发管线，加速产品上市，为全球患者带来更多福祉，为推动全球医药行业的发展贡献更多力量！

Taking this recognition as a new starting point,Yunsun will continue to uphold its innovative spirit, specialize in improved new drugs, expand its technology platforms, enrich its R&D pipeline, and accelerate product commercialization. Through these efforts, the company aims to bring more benefits to patients worldwide and contribute further to the development of the global pharmaceutical industry.

云晟研新是一家聚焦于创新药/改良新药的新药研发企业，采取梯队管线开发战略，包含改良新药、小分子创新药和CGT新药在内共80余款新药与新型疗法在开发过程中。已取得24款改良新药IND受理，20款改良型新药取得临床批件，4款新药完成临床试验入组，3款新药NDA受理。
1.云晟研新拥有专业的临床团队，对未满足的临床需求有着深刻的理解，拥有专业的生物学团队，对疾病生物学和相关生物学过程有深入的理解，极大的提升新药研发效率。
2.上海子公司，延续“博志研新”在CRO/CDMO领域十二年深度耕耘及品牌美誉度，为客户提供从合成至药品上市所需的原料药、制剂研发、临床及生产服务。
3.泰州子公司，具备中美欧申报能力，严格遵循cGMP标准，提供从药品开发至商业化生产的一站式CDMO服务，也可以单独提供CMO服务，助力客户快速推进药品上市。
3.鄂州子公司，正在建设国际化新型给药系统(NDDS)生产基地，配套硬件设施及质量体系满足中国NMPA、美国FDA、欧盟GMP要求，采用国内外一流生产设备，生产工艺实现自动化，满足中美欧日产品申报和市场供给，为国内和全球客户提供全方位研发和生产服务。

Yunsun is a pharmaceutical R&D company focused on innovative drugs and Improved new drugs. Adopting a pipeline development strategy with staged portfolios, the company currently has over 80 new drugs and novel therapies in development, including improved new drugs, small-molecule innovative drugs, and cell and gene therapies (CGT). To date, Yunsun has obtained IND acceptance for 24 improved new drugs, received clinical approval for 20 improved new drugs, completed patient enrollment in clinical trials for 4 new drugs, and achieved NDA acceptance for 3 new drugs.

1.Yunsun has a professional clinical team with deep insights into unmet clinical needs, as well as an expert biology team possessing extensive understanding of disease biology and related biological processes. This significantly enhances the efficiency of new drug development.

2.The Shanghai subsidiary, building upon Bocimed’s twelve years of in-depth experience and strong reputation in the CRO/CDMO field, offers integrated services from synthesis to drug commercialization—including APIs, formulation R&D, clinical support, and manufacturing.

3.The Taizhou subsidiary is capable of supporting regulatory filings in China, the U.S., and Europe. Strictly adhering to cGMP standards, it provides end-to-end CDMO services from drug development to commercial production, along with standalone CMO offerings, helping clients accelerate drug approval and launch.

4.The Ezhou subsidiary is constructing an international advanced production base for Novel Drug Delivery Systems (NDDS). Equipped with state-of-the-art production facilities and a quality system compliant with China NMPA, U.S. FDA, and EU GMP requirements, the site features automated manufacturing processes. It aims to support regulatory submissions and market supply in China, the U.S., Europe, and Japan, delivering comprehensive R&D and manufacturing services to domestic and global clients.